Navigation Links
Hospira Receives FDA Approval for Six New Presentations of Heparin
Date:8/31/2009

LAKE FOREST, Ill., Aug. 31 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's applications for six new presentations of therapeutic heparin in single- and multiple-dose vials.

Heparin is used to prevent clot formation in central venous catheters and for anticoagulant (blood thinning) therapy, and is available in numerous delivery systems for different modes of administration. The six new vial presentations of heparin approved by the FDA range in volume from one milliliter to 30 milliliters, and in concentration from 1,000 units per milliliter to 10,000 units per milliliter.

Hospira recognizes the clinical need for this important medication and sought to expand its marketed portfolio of heparin presentations to help meet market demand. With the addition of the new vials, Hospira now offers one of the broadest portfolios of heparin available on the U.S. market, with various sizes and strengths of the product available in syringes, vials and flexible containers.

"Hospira is committed to ensuring patient access to safe and effective supplies of heparin," said Joshua Gordon, vice president, Specialty Pharmaceuticals, Hospira. "These additional presentations will provide our customers a wide range of options to address the continuum of care."

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
2. Hospira to Present at the Credit Suisse Phoenix Health Care Conference on November 13
3. Hospira Reports Third-Quarter 2007 Results
4. Hospira to Present at the JPMorgan 26th Annual Healthcare Conference on January 9
5. Hospira Hosts Conference Call for Fourth-Quarter 2007 Results and 2008 Projections
6. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
7. Hospira Launches Generic Irinotecan Injection
8. Hospira Reports Fourth-Quarter and Full-Year 2007 Results
9. Hospira to Present at the Bear Stearns 10th Annual London Healthcare Conference on March 13
10. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
11. Hospira Acquires Sculptor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona ... Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and ... products to the store is just one more way Shamangelic Healing supports people’s ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... reveals that infants born with severe congenital diaphragmatic hernia have better survival rates ... with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent Marketing ... an exercise invention which aids in proper muscle development. , "The Gym & ... Creative Director of World Patent Marketing. "Globalization has threatened the future growth of ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, 2016 , ... New York City based ... surgery . This surgery is a very effective way to treat obstructive sleep apnea. Dr. ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, announced ... 2016 conference, presented by Joseph Gunnar & Co. ... New York . Nadav Kidron , CEO of ... Presentation Details:   PIONEERS 2016, presented ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, ... Lifecycle Management Solutions (VLMS) today announced that ... services for sufferers of chronic kidney failure ... to manage their corporate validation process. The ... a software solution to manage their validation ...
(Date:4/28/2016)... 28, 2016 New market ... is a report that provides an overview of ... pipelines by identifying new targets and MOAs to ... Profiles discussed in this H1 2016 Osteoarthritis Pipeline ... AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios ...
Breaking Medicine Technology: